Clinical Trials on Patella Luxation

Total 1159 results

Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
Allist Pharmaceuticals, Inc.

Unknown

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

China
University Hospital, Antwerp
University Hospital, Ghent

Recruiting

Genome-wide Epistasis for Cardiovascular Severity in Marfan Study (GEMS)

Marfan Syndrome | FBN1 Mutation

Belgium
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Princess Nourah Bint Abdulrahman University
King Faisal Specialist Hospital & Research Center; King Fahad Hospital

Recruiting

Estimating Length of Endotracheal Tube Insertion Using Gestational Age or Nasal-Tragus Length in Newborn Infants (ELEGANT)

Pneumothorax | Death | Bronchopulmonary Dysplasia | Endotracheal Tube Tip Position | Duration, Ventilator

Saudi Arabia
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

KRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
University Hospital, Angers
University Hospital, Rouen; Central Hospital, Nancy, France; University Hospital... and other collaborators

Unknown

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient (FLT-THERA)

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent | No EGFR Activating Mutation

France
University of Chicago
Novartis

Terminated

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...

United States
Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

United States, Spain, Korea, Republic of, Taiwan, Italy, Australia, France
Wuhan Union Hospital, China

Recruiting

Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

CML-CP; Mutation;Suboptimal Response or Failure in TKI

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease Persistence

United States
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
University Health Network, Toronto

Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Endometrioid Tumor | TP53 Mutation

Canada
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Catholic University of the Sacred Heart

Unknown

Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer (MITO15)

BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype

Italy
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
Region Skane

Recruiting

BioMEL- Diagnostic and Prognostic Factors in Melanoma. (BioMEL)

Melanoma | Mutation | Image | Dysplastic Nevi | Melanoma in Situ | Mole (Dermatology)

Sweden
University Health Network, Toronto
Pfizer

Recruiting

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | ROS1 Gene Rearrangement | MET Activating Mutation | MET Amplification

Canada
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
AstraZeneca

Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Activating Mutation

United States
Oncoethix GmbH

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Eloxx Pharmaceuticals, Inc.

Terminated

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Genetic Disease | Cystinosis | Nonsense Mutation

Canada
General Hospital of Ningxia Medical University

Unknown

The Clinical Research on the Relationship Between Circadian Rhythm and Gut Microbiota in TBI Patients

Traumatic Brain Injury | Loss of Consciousness of Unspecified Duration | Cerebral Laceration and Contusion

China
John Mascarenhas
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... and other collaborators

Completed

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

IDH2 Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Chronic-phase Myelofibrosis

United States, Canada
Technische Universität Dresden

Terminated

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (RadioCoBRIM)

Brain Metastases | Malignant Melanoma Stage IV | BRAF V600 Mutation

Germany
Nationwide Children's Hospital

Active, not recruiting

Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care (SSTIBE)

Abscess | Cellulitis | Drain Abscess | Behavioral Economics | Impetigo | Skin Infection | Antibiotic Duration

United States
Samsung Medical Center
AstraZeneca

Completed

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
Aspire Nutrition, LLP

Not yet recruiting

Impact of Mindfulness Program on Perceived Wellness, Eating Habits and Relationship to Food

Nutrition Disorders | Mental Fatigue | Dietary Habits | Diet, Healthy | Eating Disorders | Eating Behavior | Food Habits | Mental Stress | Nutrition Poor | Mental Health Issue | Nutrition, Healthy | Eating, Compulsive | Eating Disorder Weight Fixation
University Health Network, Toronto

Recruiting

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP)

Endometrial Carcinoma | P53 Mutation | Serous Carcinoma

Canada
University Medical Center Groningen
Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation

Netherlands, France
Lei Li

Recruiting

Genetic Mutation in Recurrent Cervical Cancer

Microsatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1

China
UNICANCER
Merck Sharp & Dohme LLC; Pierre Fabre Medicament; European Association of Dermato...

Recruiting

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)

Brain Metastases | Malignant Melanoma | BRAF V600 Mutation

France
Lei Li

Unknown

A Training Set for the HRD Model in EOC

Epithelial Ovarian Cancer | Homologous Recombination Deficiency | Prognosis | BRCA Mutation | Loss of Heterozygosity | Platinum Resistance

China
FORUM Pharmaceuticals Inc

Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Granulin Mutation

Belgium, United States, France, Italy, Netherlands, United Kingdom
Khondrion BV
Julius Clinical; ProPharma Group; Europees Fonds voor Regionale Ontwikkeling... and other collaborators

Recruiting

The KHENERGYC Study

Mitochondrial Diseases | MELAS | Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Subacute Necrotizing Encephalomyelopathy

Netherlands
McMaster University
Canadian Institutes of Health Research (CIHR); Technology Evaluation in the... and other collaborators

Completed

Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial (PROSPECT)

Antibiotic-Associated Diarrhea | Ventilator Associated Pneumonia (VAP) | Other Infections | C-Difficile | Duration of Mechanical Ventilation | Length of ICU Stay | Length of Hospital Stay | ICU and Hospital Mortality

United States, Canada
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Associazione Italiana per lo Studio del Pancreas

Recruiting

Registry of Subjects at Risk of Pancreatic Cancer (IRFARPC)

Lynch Syndrome | BRCA1 Mutation | BRCA2 Mutation | Familial Pancreatic Cancer | Hereditary Pancreatitis | Peutz-Jeghers Syndrome | FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
Columbia University
National Institute on Aging (NIA)

Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Lumbar Spinal Stenosis | Cardiomyopathy, Hypertrophic | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation | ATTRV122I Amyloidosis

United States
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
Rutgers, The State University of New Jersey
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Recruiting

Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers

Parkinson Disease | Cognitive Decline | Parkinson | Genetic Predisposition | GBA Gene Mutation

United States
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States

Clinical Trials on Patella Luxation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations